-$0.67 Earnings Per Share Expected for Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) This Quarter

Equities analysts predict that Eledon Pharmaceuticals, Inc. (NASDAQ:ELDNGet Rating) will post earnings of ($0.67) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Eledon Pharmaceuticals’ earnings. The highest EPS estimate is ($0.66) and the lowest is ($0.67). Eledon Pharmaceuticals posted earnings per share of ($0.57) during the same quarter last year, which suggests a negative year over year growth rate of 17.5%. The business is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Eledon Pharmaceuticals will report full year earnings of ($2.73) per share for the current year, with EPS estimates ranging from ($4.24) to ($2.00). For the next year, analysts expect that the business will report earnings of ($1.65) per share, with EPS estimates ranging from ($1.93) to ($1.34). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Eledon Pharmaceuticals.

Eledon Pharmaceuticals (NASDAQ:ELDNGet Rating) last announced its earnings results on Thursday, March 24th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.16.

ELDN has been the topic of a number of recent research reports. Zacks Investment Research raised shares of Eledon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 25th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eledon Pharmaceuticals in a research report on Tuesday, March 29th. Lifesci Capital reiterated an “outperform” rating on shares of Eledon Pharmaceuticals in a research report on Friday, March 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Eledon Pharmaceuticals in a research report on Friday, January 14th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $29.00.

Hedge funds and other institutional investors have recently modified their holdings of the business. Morgan Stanley purchased a new stake in shares of Eledon Pharmaceuticals during the 1st quarter worth $124,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Eledon Pharmaceuticals during the 3rd quarter worth $103,000. Millennium Management LLC boosted its position in shares of Eledon Pharmaceuticals by 23.3% during the 2nd quarter. Millennium Management LLC now owns 17,993 shares of the company’s stock worth $142,000 after purchasing an additional 3,405 shares in the last quarter. Ameritas Advisory Services LLC purchased a new stake in shares of Eledon Pharmaceuticals during the 4th quarter worth $107,000. Finally, Renaissance Technologies LLC boosted its position in shares of Eledon Pharmaceuticals by 87.9% in the 3rd quarter. Renaissance Technologies LLC now owns 39,663 shares of the company’s stock worth $245,000 after buying an additional 18,556 shares in the last quarter. Institutional investors own 75.70% of the company’s stock.

Shares of Eledon Pharmaceuticals stock opened at $3.20 on Friday. The firm’s fifty day simple moving average is $3.57 and its 200-day simple moving average is $4.34. The stock has a market capitalization of $45.78 million, a price-to-earnings ratio of -1.38 and a beta of 1.92. Eledon Pharmaceuticals has a 12 month low of $2.65 and a 12 month high of $11.69.

About Eledon Pharmaceuticals (Get Rating)

Eledon Pharmaceuticals, Inc, clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.

Featured Stories

Get a free copy of the Zacks research report on Eledon Pharmaceuticals (ELDN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.